News
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1
Jaguar Health receives $16M upfront payment in U.S. license agreement with Future Pak for crofelemer drugs. Presentation at ESPGHAN 2026 reveals positive results of crofelemer therapy for pediatric IF -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog
Jaguar Health introduces Neonorm Dog, a plant-based product supporting stool consistency & GI balance for dogs. Expected to be available on Amazon & Chewy
